NUS · Nu Skin Enterprises, Inc.

Nu Skin Enterprises delivered Q1 2026 revenue of $320.6 million, within guidance and down 12.0% year-over-year on a reported basis, or 13.1% constant currency, reflecting declines across all major regions including Americas (-16.3%), South Korea (-22.1%), and Rhyz segments (-16.4%). Gross margin contracted slightly to 66.9% from 67.8%, with Nu Skin business stable at 76.9%, while selling expenses rose to 34.3% of revenue due to strategic investments, and G&A held near prior levels. Operating margin improved to 1.3% from -2.7%, bolstered by lower impairment ($1.8M vs. $25.1M) and shift from prior-year's $28.1M unrealized investment loss to $2.8M other income, though interest expense increased to $4.3M. GAAP EPS fell sharply to $0.04 from $2.14, impacted by prior-year one-time gain from Mavely sale; adjusted EPS was $0.14 vs. $0.23. Sales force metrics showed customer base down 14% to 669,535, paid affiliates off 8% to 120,850, and sales leaders down 13% to 26,915, with some stabilization in Americas paid affiliates. CEO Ryan Napierski highlighted progress on Prysm iO™ integration for sales leader scaling, Tru Face® anti-aging, India launch in late 2026, and emerging market expansion amid volatility. CFO Chelsea Lantz noted $8M shareholder returns and debt refinancing for liquidity. Guidance reaffirmed for FY2026 revenue $1.35-1.50B and adjusted EPS $0.80-1.20, signaling confidence in wellness platform and operational discipline to drive recovery.